Premium
P1‐293: GLUTAMATERGIC CONCENTRATION AS A BIOMARKER OF MEMORY PERFORMANCE IN AGING INDIVIDUALS
Author(s) -
Schoemaker Dorothee,
Near Jamie,
Gauthier Serge,
Pruessner Jens
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.533
Subject(s) - glutamatergic , hippocampus , glutamate receptor , episodic memory , neuroscience , psychology , population , audiology , medicine , cognition , receptor , environmental health
Methods: We included 50 AD patients with biological confirmation of AD pathology (Cerebro Spinal Fluid AD biomarkers and amyloid imaging by PIB-PET). Patients were divided into EOAD (n1⁄427) and LOAD (n1⁄423) groups on the basis of their estimated age at first symptom (less or greater than 65 years old).For each subject, an automated method (BrainVisa) was used to calculate sulcal width in the whole brain. We grouped the sulci in 18 regions of interest (ROI) according to AD neuropathological knowledge. Hippocampal volumes (HV) were segmented with an automated method (SACHA). Results: Mean age at disease onset was 56.3 6 5.4 years for EOAD patients (n1⁄427) and 72.2 6 7.2 yearsfor LOAD patients(n1⁄423). The distribution of global severity of the disease assessed by the Clinical Dementia Rating (CDR) scale was similar in both groups (n1⁄414 EOAD and n1⁄415 LOAD with CDR 1⁄4 0.5). Direct comparison between groups revealed a higher enlargement of the precuneus sulcus in the EOAD group (p>0,007), without significant difference in other sulcal widths. Mean hippocampal volume did not differ significantly between the two groups (p1⁄4 0,096). Conclusions: When compared with LOAD, increased precuneus sulcal width is observed in EOAD patients. Our results are in agreement with previous studies suggesting that the precuneus may contribute to early onset of AD and its more severe prognosis.